首页> 外文期刊>Research and Reports in Neonatology >Congenital chylothorax: current perspectives and trends
【24h】

Congenital chylothorax: current perspectives and trends

机译:先天性乳糜胸:目前的观点和趋势

获取原文
       

摘要

Congenital chylothorax (CC) is the most common cause of pleural effusion in the perinatal period. The etiology is unknown in the majority of the cases. However, in some cases, it can be associated with various syndromes and genetic conditions. CC is associated with a high mortality rate. Most of the clinical manifestations are secondary to pressure effects (pulmonary hypoplasia) and loss of protein and lymphatic fluid (hydrops, malnutrition). Conservative management in the neonatal period is effective in up to 80% of cases and includes pleural drainage, parenteral nutrition/enteral medium-chain triglyceride-based formulae, and medications such as octreotide. Surgical intervention (pleurodesis, thoracic duct ligation/embolization, pleuroperitoneal shunt) may be required in persistent cases. A universal consensus on management of CC is unavailable, and data on the safety of medication use for CC in neonates are sparse.
机译:先天性乳糜胸(CC)是围产期胸腔积液的最常见原因。在大多数情况下,病因不明。但是,在某些情况下,它可能与各种综合症和遗传状况有关。 CC与高死亡率相关。大多数临床表现是继发于压力作用(肺发育不全)以及蛋白质和淋巴液的丢失(积水,营养不良)。新生儿期的保守治疗在多达80%的病例中有效,包括胸膜引流,肠胃外营养/基于肠内中链甘油三酯的配方以及奥曲肽等药物。持续病例可能需要手术干预(胸膜固定术,胸导管结扎/栓塞,胸膜腹膜分流)。目前尚无关于CC的管理的普遍共识,并且有关新生儿CC的药物使用安全性的数据很少。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号